These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9927270)

  • 1. Vancomycin use in a hospital with vancomycin restriction.
    Roghmann MC; Perdue BE; Polish L
    Infect Control Hosp Epidemiol; 1999 Jan; 20(1):60-3. PubMed ID: 9927270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Hospital Infection Control Practice Advisory Committee.
    Salemi C; Becker L; Morrissey R; Warmington J
    Clin Perform Qual Health Care; 1998; 6(1):12-6. PubMed ID: 10177043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vancomycin-resistant enterococci . Work Group Hospital Infection Epidemiology].
    Endtz HP; van Belkum A; van Duin J
    Ned Tijdschr Geneeskd; 1997 Jan; 141(2):108-9. PubMed ID: 9036340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The superbug battle. One hospital duels drug-resistant infections with an all-encompassing program.
    Moore JD
    Mod Healthc; 1998 Nov; 28(46):33, 35. PubMed ID: 10187340
    [No Abstract]   [Full Text] [Related]  

  • 5. Appropriate vancomycin use in a Malaysian tertiary hospital based on current HICPAC recommendations.
    Islahudin F; Ong HY
    J Infect Dev Ctries; 2014 Oct; 8(10):1267-71. PubMed ID: 25313602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging resistance in Enterococcus spp.
    Heath CH; Blackmore TK; Gordon DL
    Med J Aust; 1996 Jan; 164(2):116-20. PubMed ID: 8569563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit.
    Chiu CH; Michelow IC; Cronin J; Ringer SA; Ferris TG; Puopolo KM
    Pediatr Infect Dis J; 2011 Apr; 30(4):273-8. PubMed ID: 21085051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: a population-based assessment.
    Thomas AR; Cieslak PR; Strausbaugh LJ; Fleming DW
    Infect Control Hosp Epidemiol; 2002 Nov; 23(11):683-8. PubMed ID: 12452297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin in Oregon: who's using it and why.
    Cieslak PR; Strausbaugh LJ; Fleming DW; Ling JM
    Infect Control Hosp Epidemiol; 1999 Aug; 20(8):557-60. PubMed ID: 10466557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
    Hochart C; Berthon C; Corm S; Gay J; Cliquennois M; Tricot S; Alfandari S
    Med Mal Infect; 2011 Dec; 41(12):652-6. PubMed ID: 22056376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statewide surveillance for antibiotic-resistant bacteria--New Jersey, 1992-1994.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1995 Jul; 44(27):504-6. PubMed ID: 7596335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium.
    Anglim AM; Klym B; Byers KE; Scheld WM; Farr BM
    Arch Intern Med; 1997 May; 157(10):1132-6. PubMed ID: 9164379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin-resistant enterococci: improving treatments.
    Whittle J; Queenan E
    Pa Med; 1997 Nov; 100(11):24-6. PubMed ID: 9509876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bloodstream infections with vancomycin-resistant enterococci.
    Montecalvo MA; Shay DK; Patel P; Tacsa L; Maloney SA; Jarvis WR; Wormser GP
    Arch Intern Med; 1996 Jul; 156(13):1458-62. PubMed ID: 8678715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vancomycin resistant enterococci in Austria].
    Allerberger F; Lass-Flörl C; Dierich MP; Hirschl AM; Presterl E; Haas G; Klare I; Witte W
    Wien Klin Wochenschr; 1997 May; 109(9):312-20. PubMed ID: 9265389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin-resistant enterococci in hemodialysis patients is related to intravenous vancomycin use.
    Fishbane S; Cunha BA; Mittal SK; Ruggian J; Shea K; Schoch PE
    Infect Control Hosp Epidemiol; 1999 Jul; 20(7):461-2. PubMed ID: 10432156
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of glycopeptide use in nine French hospitals.
    Alfandari S; Levent T; Descamps D; Hendricx S; Bonenfant C; Taines V; Cattoen C; Arimane O; Grandbastien B
    Med Mal Infect; 2010 Apr; 40(4):232-7. PubMed ID: 19959309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality.
    Lautenbach E; Bilker WB; Brennan PJ
    Infect Control Hosp Epidemiol; 1999 May; 20(5):318-23. PubMed ID: 10349947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin-resistant enterococci on a renal ward in an Ontario hospital.
    Lior L; Litt M; Hockin J; Kennedy C; Jolley BA; Garcia M; Gillis G; Humar A; Campbell I; Brunton J; Dedier H; Conly J
    Can Commun Dis Rep; 1996 Aug; 22(15):125-8. PubMed ID: 8791860
    [No Abstract]   [Full Text] [Related]  

  • 20. [First infection with vancomycin resistant type VanA enterococci in a Norwegian hospital].
    Haarr E; Simonsen GS; Olsvik O; Sundsfjord A; Harbo K; Natås OB
    Tidsskr Nor Laegeforen; 1998 Mar; 118(8):1188-90. PubMed ID: 9567694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.